Arrowhead Pharmaceuticals Launches 'We'll Get There Soon' Campaign for FCS Awareness

Arrowhead Pharmaceuticals Launches Awareness Campaign for Rare Disease FCS

Arrowhead Pharmaceuticals, Inc. has taken a significant step in supporting the rare disease community by launching the 'We'll Get There Soon' campaign on Familial Chylomicronemia Syndrome (FCS) Awareness Day. FCS is a severe genetic condition characterized by extremely high triglyceride levels, often exceeding 880 mg/dL, which can lead to serious health complications such as acute pancreatitis. The company's new campaign aims to educate the public about the condition and its management, as well as to foster a supportive community for those affected. Through a dedicated website, www.LowerTriglycerides.com, and active social media engagement, Arrowhead encourages individuals to learn more about maintaining healthy triglyceride levels—ideally below 500 mg/dL according to expert guidelines.

During the campaign's launch event at Arrowhead's headquarters in Pasadena, guest speaker Julie Klueckman shared her personal experiences with FCS, highlighting the challenges of living with the disease. Klueckman’s journey included multiple misdiagnoses and lengthy hospital stays, alongside the rigorous demands of adhering to a severely restricted diet of only 20 grams of fat per day. Her story not only underscores the complexities of FCS but also reflects a broader sentiment of hope for advancements in treatment. Klueckman is actively collaborating with Arrowhead to provide patient insights that could influence future therapeutic strategies, demonstrating the company’s commitment to patient-centric approaches.

Alexendra Roeser, Director of Patient Advocacy at Arrowhead, reiterated the company’s dedication to amplifying the voices of those affected by FCS. Roeser emphasizes the importance of community support and education in managing this challenging condition. The 'We'll Get There Soon' campaign is a testament to Arrowhead's mission to enhance patients' lives and raise awareness about FCS, positioning the company as a leader in patient advocacy within the pharmaceutical industry. As Arrowhead works to bridge the information gap surrounding this rare disease, the campaign not only provides hope to patients but also fosters a sense of solidarity among those navigating the complexities of FCS.

In conjunction with this initiative, Arrowhead Pharmaceuticals is committed to continuous engagement with the FCS community. By providing a platform for education and sharing experiences, the company aims to empower patients and their families. Those interested in learning more about FCS and available resources can visit www.LowerTriglycerides.com for further information.